Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie C Edwards

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Endourology|June 15, 2024
Artificial Intelligence in Endourology: Maximizing the Promise Through Consideration of the Principles of Diffusion of Innovation TheoryManoj Monga, Natalie C Edwards, Sirikan Rojanasarot, et al.
American Journal of Men'S Health|October 13, 2020
Addressing Health-Care System Inequities in the Management of Erectile Dysfunction: A Call to ActionArthur L Burnett, Natalie C Edwards, Tonya M Barrett, et al.
Sexual Medicine Reviews|November 4, 2021
The Epidemic of COVID-19-Related Erectile Dysfunction: A Scoping Review and Health Care PerspectiveTung-Chin Hsieh, Natalie C Edwards, Samir K Bhattacharyya, et al.
Pharmacoeconomics|April 20, 2005
Cost-effectiveness model of long-acting risperidone in schizophrenia in the USNatalie C Edwards, Marcia F T Rupnow, Chris L Pashos, et al.
BMC Neurology|July 16, 2020
Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysisJacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, et al.
Current Medical Research and Opinion|October 29, 2008
One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophreniaNatalie C Edwards, Jacqueline Pesa, Dennis M Meletiche, et al.
Journal of Managed Care Pharmacy : JMCP|September 11, 2009
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosisLawrence D D Goldberg, Natalie C Edwards, Contessa Fincher, et al.
International Journal of MS Care|September 18, 2023
Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature ReviewAliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 7, 2022
Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapyJacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumRafael V Lippert, A Zarina Kraal, Natalie C Edwards, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Endourology|June 15, 2024
Artificial Intelligence in Endourology: Maximizing the Promise Through Consideration of the Principles of Diffusion of Innovation TheoryManoj Monga, Natalie C Edwards, Sirikan Rojanasarot, et al.
American Journal of Men'S Health|October 13, 2020
Addressing Health-Care System Inequities in the Management of Erectile Dysfunction: A Call to ActionArthur L Burnett, Natalie C Edwards, Tonya M Barrett, et al.
Sexual Medicine Reviews|November 4, 2021
The Epidemic of COVID-19-Related Erectile Dysfunction: A Scoping Review and Health Care PerspectiveTung-Chin Hsieh, Natalie C Edwards, Samir K Bhattacharyya, et al.
Pharmacoeconomics|April 20, 2005
Cost-effectiveness model of long-acting risperidone in schizophrenia in the USNatalie C Edwards, Marcia F T Rupnow, Chris L Pashos, et al.
BMC Neurology|July 16, 2020
Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysisJacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, et al.
Current Medical Research and Opinion|October 29, 2008
One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophreniaNatalie C Edwards, Jacqueline Pesa, Dennis M Meletiche, et al.
Journal of Managed Care Pharmacy : JMCP|September 11, 2009
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosisLawrence D D Goldberg, Natalie C Edwards, Contessa Fincher, et al.
International Journal of MS Care|September 18, 2023
Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature ReviewAliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 7, 2022
Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapyJacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumRafael V Lippert, A Zarina Kraal, Natalie C Edwards, et al.
Pageof 4